Trinity’s Dr David Finlay, ONK’s Prof Michael O’Dwyer and  Enterprise Ireland’s Lawrence Lee: “In working with Dr Finlay, we are collaborating with the pioneering expert in the field of NK immunometabolism,” says Prof O’Dwyer. Photograph: Chris Bellew

ONK Therapeutics, a Galway company developing enhanced natural killer cells in the immune system to target cancers, is teaming up with Trinity College(...)

Drug delivery business Avectas has licensed a therapy from Galway-based ONK Therapeutics that targets what are called B-cell malignancies – blood cell cancers such as non-Hodgkin’s lymphoma (above)

Two cutting edge Irish pharmaceutical companies have announced a deal that they hope will deliver significantly improved treatment for people with cer(...)